Clayton Robertson

Clayton joined Immunocore in 2021. Most recently, he served as Director of Investor Relations at Actinium Pharmaceuticals (ATNM) and PureTech Health (PRTC). Prior to that, he led the investor relations efforts at Achillion Pharmaceuticals. He began his career in biotech investor relations and capital markets at The Trout Group, a premier life sciences advisory firm. Clayton holds a bachelor of arts degree from the University of Pennsylvania.